Astria Therapeutics (Astria Therapeutics) Capex-to-Operating-Income : 0.00 (As of Dec. 2023)

View and export this data going back to 2015. Start your Free Trial

What is Astria Therapeutics Capex-to-Operating-Income?

Capex-to-Operating-Income measures a company's investments in physical assets such as property, industrial buildings or equipment to its operating income.

Astria Therapeutics's Capital Expenditure for the three months ended in Dec. 2023 was $-0.02 Mil. Its Operating Income for the three months ended in Dec. 2023 was $-19.00 Mil.

GuruFocus do not calculate Capex-to-Operating-Income if the Operating Income is negative.

Astria Therapeutics Capex-to-Operating-Income Historical Data

The historical data trend for Astria Therapeutics's Capex-to-Operating-Income can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Astria Therapeutics Capex-to-Operating-Income Chart

Astria Therapeutics Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Capex-to-Operating-Income

Get a 7-Day Free Trial

Astria Therapeutics Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Capex-to-Operating-Income	Get a 7-Day Free Trial															-	-	-	-	-

Competitive Comparison of Astria Therapeutics's Capex-to-Operating-Income

For the Biotechnology subindustry, Astria Therapeutics's Capex-to-Operating-Income, along with its competitors' market caps and Capex-to-Operating-Income data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Astria Therapeutics's Capex-to-Operating-Income Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Astria Therapeutics's Capex-to-Operating-Income distribution charts can be found below:

* The bar in red indicates where Astria Therapeutics's Capex-to-Operating-Income falls into.

Astria Therapeutics Capex-to-Operating-Income Calculation

Astria Therapeutics's Capex-to-Operating-Income for the fiscal year that ended in Dec. 2023 is calculated as

Capex-to-Operating-Income	=	- Capital Expenditure	/	Operating Income
	=	- (-0.025)	/	-67.831
	=	N/A

Astria Therapeutics's Capex-to-Operating-Income for the quarter that ended in Dec. 2023 is calculated as

Capex-to-Operating-Income	=	- Capital Expenditure	/	Operating Income
	=	- (-0.016)	/	-19
	=	N/A

Astria Therapeutics (NAS:ATXS) Capex-to-Operating-Income Explanation

Capex-to-Operating-Income assesses how much emphasis a company is placing upon investing in capital-intensive projects. The ratio is generally a good gauge to quantify how much focus on growth a company has. Typically, smaller companies that are still growing and expanding will have a higher Capex to Operating Income Ratio, since such businesses are likely investing more in physical assets. Lower ratios could indicate that a company has reached maturity and it is no longer pursuing aggressive growth.

Astria Therapeutics Capex-to-Operating-Income Related Terms

Thank you for viewing the detailed overview of Astria Therapeutics's Capex-to-Operating-Income provided by GuruFocus.com. Please click on the following links to see related term pages.

Astria Therapeutics (Astria Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Astria Therapeutics Inc (NAS:ATXS) » Definitions » Capex-to-Operating-Income

Comparable Companies

Traded in Other Exchanges

N/A

Address

75 State Street, Suite 1400, Boston, MA, USA, 02109

Website

https://www.astriatx.com

Astria Therapeutics Inc is a biopharmaceutical company engaged to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Its lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in preclinical development for the treatment of hereditary angioedema.

Executives

Perceptive Life Sciences Master Fund Ltd	director, 10 percent owner	C/O PERCEPTIVE ADVISORS LLC, 51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003
Andrea Matthews	officer: Chief Business Officer	C/O ASTRIA THERAPEUTICS, INC., 75 STATE STREET, SUITE 1400, BOSTON MA 02109
Christopher Morabito	officer: Chief Medical Officer	C/O FULCRUM THERAPEUTICS, INC., 26 LANDSDOWNE STREET, CAMBRIDGE MA 02139
Andrew Komjathy	officer: Chief Commercial Officer	CATABASIS PHARMACEUTICALS, INC., ONE KENDALL SQUARE, SUITE B14202, CAMBRIDGE MA 02139
Andrew John Nichols	officer: Chief Scientific Officer	C/O CATABASIS PHARMACEUTICALS, INC., ONE KENDALL SQUARE, BLDG 1400E, CAMBRIDGE MA 02139
Perceptive Xontogeny Venture Fund, Lp	director, 10 percent owner	C/O PERCEPTIVE ADVISORS, 51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003
Jonathan Violin	director	955 CHESTERBROOK BOULEVARD, SUITE 200, CHESTERBROOK PA 19087
Fred Callori	director	100 HIGH STREET, 28TH FLOOR, BOSTON MA 02110
Xontogeny, Llc	director, 10 percent owner	51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003
Perceptive Advisors Llc	director, 10 percent owner	51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003
Joseph Edelman	director, 10 percent owner	C/O PERCEPTIVE ADVISORS LLC, 51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003
Joanne T. Beck	director	C/O CATABASIS PHARMACEUTICALS, INC., ONE KENDALL SQ, BLD. 1400E, SUITE B14202, CAMBRIDGE MA 02139
Anthony Gregg Lapointe	director	PO BOX 83216, GAITHERSBURG MD 20883-3216
Hugh M Cole	director	C/O ARIAD PHARMACEUTICALS, INC, 26 LANDSDOWNE STREET, CAMBRIDGE MA 02139
Benjamin Harshbarger	officer: Secretary and General Counsel	ONE MAIN STREET, SUITE 800, CAMBRIDGE MA 02142